Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2024 07:00 ET | Source: Engrail Therapeutics, Inc.

Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors

Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors
May 16, 2023 07:50 ET | Source: Incannex Healthcare

Incannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary Company

MELBOURNE, Australia, May 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation which details...
March 29, 2023 12:30 ET | Source: Future Market Insights Global and Consulting Pvt. Ltd.

Generalized Anxiety Disorder Treatment Market Size is estimated to reach US$ 4261.25 Million by 2033, growing at a CAGR of 9% during the forecast period 2023 to 2033 | Future Market Insights, Inc.

NEWARK, Del, March 29, 2023 (GLOBE NEWSWIRE) -- During the forecast period 2023 to 2033, the Generalized anxiety disorder treatment market is expected to grow at a value of 9% CAGR, according to...
March 15, 2023 07:30 ET | Source: Incannex Healthcare

Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment

Highlights: Interim analysis of study data to date indicates that there is a greater than 85% chance (>85%, alpha error probability 0.05) of the study showing a statistically significant benefit...
January 18, 2023 08:00 ET | Source: Incannex Healthcare

Independent data review commences for Phase 2 trial of psilocybin-assisted psychotherapy for anxiety

MELBOURNE, Australia, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing proprietary...
August 06, 2020 10:15 ET | Source: Allied Market Research

Antidepressant Drugs Market to Grow Valuation of $15.98 Billion by 2023

Portland, OR, Aug. 06, 2020 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research,the antidepressant drugs market accounted for $13.75 billion in 2016, and is estimated to...